Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Equilibrative nucleoside transporter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Equilibrative nucleoside transporter. Displaying page 1 of 1.
    EudraCT Number: 2007-007476-42 Sponsor Protocol Number: CP4126-201 Start Date*: 2009-01-09
    Sponsor Name:Clavis Pharma ASA
    Full Title: A phase II study of CP-4126 in patients with advanced pancreatic cancer
    Medical condition: Pancreatic Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018240-23 Sponsor Protocol Number: CO-101-001 Start Date*: 2010-07-12
    Sponsor Name:Clovis Oncology Inc
    Full Title: A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) FR (Completed) GB (Completed) SE (Completed) DE (Completed) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003287-39 Sponsor Protocol Number: PRO-105 Start Date*: 2017-07-05
    Sponsor Name:NuCana plc
    Full Title: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer
    Medical condition: Platinum-resistant epithelial cancer of the ovary, fallopian tube or primary peritoneum (here termed ‘ovarian cancer’), who have been treated with 3 or more prior chemotherapy regimens.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000363-24 Sponsor Protocol Number: Met-Dipy001 Start Date*: 2012-04-18
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: The effect of dipyridamole on the pharmacokinetics of metformin.
    Medical condition: The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or s...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10068071 Inhibitory drug interaction PT
    14.1 10018065 - General disorders and administration site conditions 10013710 Drug interaction PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008518-38 Sponsor Protocol Number: CP4055-205 Start Date*: 2009-09-30
    Sponsor Name:Clavis Pharma ASA
    Full Title: A Phase II Study of Elacytarabine plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia
    Medical condition: Acute Myeloid Leukaemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 00:27:10 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA